Objectives. We compared chronic liver disease (CLD) mortality from 1999 to 2009 between American Indians and Alaska Natives (AI/ANs) and Whites in the United States after improving CLD case ascertainment and AI/AN race classification.
In 2009, chronic liver disease (CLD) was classified as the fifth leading cause of death among American Indians and Alaska Natives (AI/ANs), accounting for 4.8% of AI/AN deaths. 1 A 2004 mortality study used a broader set of disease codes from the International Classification of Diseases, Ninth Revision (ICD-9) than was used in the National Vital Statistics System (NVSS) to define a CLD death, and reported an AI/AN age-adjusted death rate more than twice that of other races. 2 Few US population-based studies of CLD have described its prevalence among AI/AN persons. 3 Two studies found that 4.9% to 7 .2% of patients in 3 facilities serving AI/AN populations had clinically confirmed CLD. 4, 5 Both identified alcoholic liver disease (ALD), chronic HCV infection, and nonalcoholic fatty liver disease (NAFLD) as the most common contributing causes. Multiple factors limit the precision of AI/AN mortality estimates. First, racial misclassification of AI/AN individuals can affect mortality data and subsequent surveillance estimates. 6, 7 In cancer incidence studies, the Indian Health Service (IHS) has improved race classification by linking surveillance data with IHS patient enrollment records and restricting analyses to counties where AI/AN race is more accurately classified. 6 In addition, previously used ICDbased CLD definitions have underestimated CLD cases in death records. 8 A 2004 mortality study provided improved estimates of CLD deaths from 1990 to 1998 with inclusion of viral hepatitis disease codes. 2 Since then, an even more comprehensive ICD-based definition of CLD has provided more accurate estimates of clinically confirmed CLD deaths, 8, 9 but has not yet been used in national mortality studies.
In this study, we employed a comprehensive ICD-based definition of CLD deaths and used established techniques to improve race classification to accurately describe disparities and compare trends in CLD mortality from 1999 to 2009 between AI/AN persons and Whites in the United States.
METHODS
Detailed methods for analytical mortality file creation are described elsewhere in this supplement. 10 
Population Estimates
Denominators for the calculation of death rates were derived from bridged single-race population estimates developed by the US Census Bureau and the National Center for Health Statistics (NCHS), a part of the Centers for Disease Control and Prevention (CDC).
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Denominators were adjusted for population shifts caused by Hurricanes Katrina and Rita in 2005. 11, 12 The bridging of multiple races that may be reported per decedent since 2000 into 1 single recorded race enabled comparison of racial/ethnic population estimates for the entire study period. 13 
Death Records
Data from the NVSS includes all conditions and diseases reported on death certificates. These include the underlying cause of death, which is the single disease or injury that initiated the train of events leading to death, and up to 20 additional "contributing causes of death."
14 Together, these form the multiple causes of death (MCOD) contained in the US Multiple-Cause Mortality Files. Death certificate data are compiled by states and reported to the NCHS, where they are de-identified and released publicly as the National Death Index (NDI), a national file with underlying and multiple cause of death fields, state of residence, age, gender, race, and ethnicity. 15 The NCHS and Census Bureau apply nearly identical bridging algorithms to assign a single race to decedents with multiple races reported on death certificates. 13 For this study, 8 in which 83% of CLD cases identified by the comprehensive ICD-10 code list had clinically defined CLD verified by medical chart review. Thirty-eight ICD-10 codes considered in the KPNC study were excluded from our study either because they had poor reliability in predicting chart review-confirmed CLD or because they did not contribute to CLD cases in that study (unpublished observations). The resulting set of ICD-10 codes had a positive predictive value of 85% for clinically defined CLD in the KPNC medical record. For our study, a death caused by CLD was defined as any death with 1 of the following ICD-10 codes listed as the underlying cause: ALD (K70.0---K70.4, K70.9); toxic liver disease (K71.0---K71.9); liver failure (K72.0---K72.1, K72.9); chronic hepatitis (K73.0---K73. 10 Similar regional analyses were used for other AI/AN health-related publications. 6, 18, 19 Additional details about CHSDA counties and IHS regions, including population coverage, are provided elsewhere (Table 1) . 10 
Statistical Methods
Gender-specific, age-adjusted, and agespecific death rates (per 100 000 persons), are presented for deaths with CLD as the underlying cause. Age-specific death rates were calculated by age group: younger than 25 years, 25 to 44 years, 45 to 64 years, 65 to 84 years, and 85 years or older. We classified CLD deaths as either being caused by hepatocellular carcinoma (HCC) or cirrhosis, as previously described. 8 Cases with a primary liver cancer code listed as the underlying cause were considered to be attributable to HCC, whereas all non-HCC cases were considered attributable to cirrhosis. 8 
Age-Adjusted Mortality by Region and Gender
From 1999 to 2009, we identified 10 832 deaths among AI/AN persons and 434 631 deaths among Whites attributable to CLD in all counties, representing 6.7% of all deaths in AI/AN persons and 2.0% of all deaths in Whites (Table 1) . In this period, 8646 deaths among AI/ANs and 104 029 deaths among Whites attributable to CLD were found in CHSDA counties. Significant disparities in CLD mortality between AI/ANs and Whites were noted across every IHS region in analyses of all counties and CHSDA counties. Overall, CLD death rates in AI/AN persons varied substantially between CHSDA (66.1; 95% CI = 64.7, 67.6) and all counties estimates (49.9; 95% CI = 48.9, 50.9). However, variation among rates among Whites was negligible (CHSDA: 17.6; 95% CI = 17.5, 17.8 vs all counties: 16.9; 95% CI = 16.8, 16.9).
Focusing on CHSDA counties, total ageadjusted mortality varied substantially by region among AI/AN individuals, with highest rates in the Northern Plains (86.5; 95% CI = 82.3, 90.9) and the Southwest (77.9; 95% CI = 75.1, 80.9; Table 1 ). Overall rates were higher among men (78.9; 95% CI = 76.6, 81.3) than women (54.9; 95% CI = 53.1, 56.7), with similar differences regionally. However, when comparing AI/AN persons with Whites by gender, AI/AN women had a greater risk of CLD death than White women (RR = 4.7; 95% CI = 4.6, 4.9). AI/AN men had a significantly higher risk than White men (RR = 3.2; 95% CI = 3.1, 3.4), although with less of a disparity than among women. The highest regional, gender-specific death rates were noted among AI/AN men in the Northern Plains (98.3; 95% CI = 91.5, 105.5) and the Southwest (96.5; 95% CI = 91.8, 101.3). Among Whites, little regional variation in mortality was found. Again in CHSDA counties, overall, AI/AN persons were nearly 4 times more likely to die from CLD than Whites (RR = 3.7; 95% CI = 3.7, 3.8; Table 1 ). In the Northern Plains, where disparities were greatest, AI/ANs were more than 6 times more likely to die from CLD than Whites (RR = 6.4; 95% CI = 6.1, 6.8), and AI/AN women were more than 8 times more likely to die than White women (RR = 8.3; 95% CI = 7.6, 8.9). In the Southwest, AI/ ANs were 4 times more likely to die of CLD than Whites (RR = 4.0; 95% CI = 3.9, 4.2), and AI/AN women were almost 5 times more likely to die than White women (RR = 4.8; 95% CI = 4.5, 5.1). Significant disparities in genderspecific mortality were noted in every CHSDA region, with women at higher risk than men.
Age-Specific Mortality by Region
CLD death rates among AI/AN persons were significantly higher than among Whites across all adult ( ‡ 25 years) age groups ( Table 2) . Although CLD death rates were highest in AI/AN persons aged 85 years or more (163.6; 95% CI = 138.7, 191.7), disparities versus Whites were highest among persons aged 25 to 44 years; AI/AN persons of these ages were more than 7 times more likely to die from CLD than Whites (RR = 7.4; 95% CI = 7.1, 7.8). Among persons aged 25 to 44 years, AI/AN persons had a significantly higher proportion of CLD deaths among women than men (43.5% vs 37.6%; P < .001). Disparities in this age group were highest for AI/AN women, who were more than 8 times more likely to die from CLD than White women (RR = 8.3; 95% CI = 7.7, 8.9). Similarly, greater disparities between AI/AN individuals and Whites were found within the youngest adult age group in every IHS region, most notably in the Northern Plains; there, among those ages 25 to 44 years, AI/AN men were more than 11 times more likely to die from CLD than White men (RR = 11.7; 95% CI = 10.0, 13.5), and AI/AN women were 15 times more likely to die than White women (RR = 15.3; 95% CI = 13.0, 18.0).
Causes of Hepatocellular Carcinoma and Cirrhosis Mortality by Age
In CHSDA counties from 1990 to 2009, 90.1% of all CLD deaths among AI/AN persons compared with 81.0% among Whites were attributed to cirrhosis (data available as a supplement to the online version of this article at http://www.ajph.org). For 4809 (55.6%) deaths among AI/AN persons, and 46 263 (44.5%) deaths among Whites, we could assign at least 1 CLD etiology for 1 or more of ALD, HBV infection, or HCV infection based on death record data (data available as a supplement to the online version of this article at http://www.ajph.org). Although a substantial proportion of the 7790 cirrhosis-attributed deaths among AI/AN persons were identified as being associated with ALD (52.6%), HCV infection (10.7%), or HBV infection (1.0%), few HCC-related deaths among AI/AN individuals were reportedly associated with these causes (data available as a supplement to the online version of this article at http://www.ajph.org). Among 4809 deaths in AI/AN persons with an aforementioned etiology listed for a CLD death, 281 (5.8%) were associated with comorbid alcohol and HCV infection. Approximately one third (340 of 983, 34.6%) of CLD deaths with hepatitis B or hepatitis C noted had either co-infection of HBV and HCV, comorbid ALD, or both. HCV infection was the most commonly identified CLD etiology associated with an HCC-related death among AI/ANs (108 of 856; 12.6%).
Disparities in mortality between AI/AN individuals and Whites were significantly greater among cirrhosis-related deaths (RR = 4.0; 95% Note. AI/AN = American Indian/Alaska Native; APC = annual percent change; CI = confidence interval; NHW = Non-Hispanic White. Previously published chronic liver disease definition 8 using International Classification of Diseases, 10th Revision codes for underlying cause of death modified for use in this study. Death rates are per 100 000 persons and are age-adjusted to the 2000 US standard population (11 age groups; Census P25-1130). American Indian/Alaska Native race is reported from death certificates or through linkage with the Indian Health Services (IHS) patient registration database. Analyses are limited to persons of non-Hispanic origin. (AMD 1990 (AMD -2009 ). a Identifies states with at least 1 county designated as CHSDA. Percent regional coverage of AI/AN persons in CHSDA counties to AI/AN persons in all counties: Alaska = 100%; East = 14.9%; Northern Plains = 55.0%; Southern Plains = 58.0%; Pacific Coast = 54.1%; Southwest = 84.8%. * Indicates RR is statistically significant (P < .05). RRs are calculated in SEER*Stat before rounding of rates and may not equal rate ratios calculated from rates presented in the table. CI = 3.9, 4.1) compared with HCC-related deaths (RR = 2.5; 95% CI = 2.3, 2.7; Figure 2 ). Disparities in cirrhosis-related mortality were highest among adults aged 25 to 44 years, with AI/AN persons almost 8 times more likely to die of a cirrhosis-related death compared with Whites (RR = 7.7; 95% CI = 7.3, 8.1). Among cirrhosis-related deaths in which ALD, HCV infection, and HBV infection were identified as underlying or contributing causes, disparities in mortality were consistently greater in younger age groups, especially among those aged 25 to 44 years ( Figure 2 ). Significant disparities were noted for HCC-related death associated with ALD and HCV infection, but not HBV infection. Disparities in HCC-related death did not vary substantially by age.
DISCUSSION
This analysis of CLD death record data from 1999 to 2009, including correction for improved CLD case ascertainment and AI/AN race classification, showed significant disparities in national and regional CLD mortality between AI/AN persons and Whites more than previously reported.
2 CLD mortality significantly increased from 1999 to 2009 among AI/AN persons and Whites. Overall age-adjusted CLD mortality was almost 4 times greater among AI/AN individuals than Whites. These CLD death rates were more than 3 times higher than 2009 rates from the NVSS 1 and more than twice the rates described in the study of 1990 to 1998 deaths. 2 Death rates among AI/AN persons and disparities versus Whites were greatest in the Northern Plains and the Southwest. We found that AI/AN populations compared with Whites had significantly higher CLD death rates across all age groups, Note. Previously published chronic liver disease definition 8 using International Classification of Diseases, 10th Revision (ICD-10) codes for underlying cause of death modified for use in this study. Hepatocellular carcinoma-related death was defined as having an ICD-10 code for a primary liver cancer as the underlying cause. Cirrhosis-related death was assigned to all other chronic liver disease (CLD). American Indian/Alaska Native race is reported from death certificates or through linkage with the Indian Health Services patient registration database. Analyses are limited to persons of non-Hispanic origin. Selected causes (cirrhosis and hepatocellular carcinoma) were determined from ICD-10 codes for underlying or contributing cause of death. Cases with multiple CLD causes are counted more than once. Death rates are per 100 000 persons and are age-adjusted to the 2000 US standard population (11 age groups; Census P25-1130). especially those aged 25 to 44 years, mainly from cirrhosis-attributed deaths (vs HCCattributed deaths). These findings suggested that a substantial proportion of AI/AN individuals compared with Whites with CLD might be dying of cirrhosis at earlier ages, precluding age-dependent increases in HCC risk. Disparities in CLD mortality among AI/AN persons and Whites who had ALD, HCV, or HBV as an underlying or contributing cause of death, suggested that AI/AN individuals with any of those conditions were more likely to die of a cirrhosis-related death than Whites, particularly early in adulthood. Although the rate of CLD-related death was highest among men, greater overall disparities in mortality were noted between AI/AN and White women, especially at earlier ages. ALD, which was reported as the underlying cause of more than half of CLD deaths in AI/AN persons in this study, contributed substantially to this disparate burden of premature mortality. Also, dual disease conditions were common, usually involving ALD. More than one-third of the CLD deaths attributed to hepatitis B or C in death records noted either co-infections, ALD, or both. HIV is also associated with elevated liver disease mortality, particularly with comorbid viral hepatitis, 23 but we found few HIV deaths relative to CLD deaths, precluding analysis of this association. Overall, these findings confirmed that CLD is a leading cause of premature mortality in the male and female AI/AN population, and that the disparity with Whites was much greater than previously described. NAFLD has not yet been shown to impact US mortality, the finding that advanced fibrosis in persons with NAFLD is associated with increased mortality suggests that the mortality burden might change in the future. 36, 37 Metabolic syndrome, a common precursor to NAFLD, is a significant risk factor in the development of HCC. 43 Linkages between the AMD and the IHS patient encounter data would enable more detailed analyses of the prospective impact of NAFLD on CLD mortality. Our findings were subject to several limitations. First, data linkages and analyses by CHSDA counties did not correct misclassification of AI/AN race of persons not affiliated with a federal tribe or IHS care. Thus, AI/AN persons living in urban areas were likely underrepresented. Second, exclusion of Hispanic AI/AN individuals from the analysis reduced overall count of deaths among AI/AN persons by less than 5%, but might disproportionately affect some states. Third, there was substantial variation between federally recognized tribes in the proportion of native ancestry required for tribal membership, and therefore, for eligibility for IHS services. Whether and how this discrepancy in tribal membership requirements might influence some of our findings was unclear, although our findings were consistent with previous reports. Fourth, although our ICD-10 definition for CLD deaths was validated by medical chart review in a large integrated health care population, 8 we acknowledge that coding practices vary among clinical settings as may the positive predictive value of ICD-10 codes chosen to define CLD deaths. Fifth, cause-specific mortality data is known to be limited because of errors in diagnosis and reporting of cause of death. 44 Etiologies were assigned based on death records in our study and should not be confused with actual cause-specific disease burden. Underlying CLD etiologies are substantially undercounted in death records, 8, 41 and thus, rates associated with specific etiologies are likely higher than reported. NAFLD-related mortality is particularly difficult to describe using death records because standardized ICD-10 codes to identify NAFLD are lacking. Finally, although etiologies of CLD might vary in impact regionally, analysis of etiologies by region was limited by the small numbers in such subgroups. The disparate CLD mortality burden, particularly from premature death, among AI/AN persons compared with Whites, and the substantial regional variations found here could help direct resource allocation for primary and secondary prevention strategies targeting the AI/AN population. Strategies to improve the prompt diagnosis of CLD and linkage to care and management of underlying diseases are essential. These are important considerations with the expected expansion of insurance coverage for AI/AN individuals under the Affordable Care Act. Increased resources are also urgently needed for proven prevention and integrated care strategies, including treatment and counseling for alcohol abuse and dependence, harm reduction strategies for persons who inject drugs, programs to address obesity and metabolic syndrome, sustained HAV and HBV vaccination efforts among CLD cases, and access to affordable, curative HCV treatment. Such integrated, comprehensive approaches are necessary to stem the burden of CLD mortality among AI/AN persons in the United States. j
